Rezdiffra (Resmetirom) Real-World Evidence: What Registries and RWE Show Beyond Clinical Trials

How Resmetirom Works: The THR-Beta Mechanism

Resmetirom is a liver-directed, orally bioavailable thyroid hormone receptor-beta (THR-beta) agonist. It selectively activates THR-beta in hepatocytes without meaningful activity at THR-alpha receptors in the heart, bone, or hypothalamic-pituitary-thyroid axis. This selectivity is what separates it from earlier, non-selective thyroid hormone analogs that caused tachycardia and bone loss.

The drug reduces intrahepatic triglyceride content by upregulating mitochondrial beta-oxidation of fatty acids and increasing very-low-density lipoprotein (VLDL) secretion and clearance. In parallel, THR-beta activation lowers circulating LDL cholesterol by increasing hepatic LDL receptor expression, mimicking one arm of thyroid hormone's lipid-lowering effects 1.

At a molecular level, resmetirom binds THR-beta with approximately 28-fold selectivity over THR-alpha. This ratio, established in preclinical receptor-binding assays published by Madrigal, explains the absence of clinically significant cardiac effects observed through 54 months of trial follow-up. The drug's hepatic first-pass extraction concentrates it in the target organ, yielding liver-to-plasma concentration ratios exceeding 5:1 in rodent pharmacokinetic studies 2.

The downstream effects on MASH pathology are threefold: reduced lipotoxicity from intracellular lipid accumulation, decreased stellate cell activation (the primary driver of fibrogenesis), and reduced hepatic inflammation as measured by ALT normalization. In MAESTRO-NASH, ALT levels dropped by a mean of 20 U/L from baseline at 24 weeks, with 55% of resmetirom-treated patients achieving normal ALT versus 31% on placebo 1.

MAESTRO-NASH: The Key Efficacy Foundation

Before examining real-world data, the trial results provide the benchmark. MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and stage F1B-F3 fibrosis across 200 sites in 14 countries. The co-primary endpoints at week 52 were NASH resolution (ballooning = 0, inflammation score 0-1) without fibrosis worsening, and fibrosis improvement by at least one stage without NASH worsening 1.

Results at 52 weeks: 25.9% of patients on resmetirom 80 mg achieved NASH resolution versus 9.7% on placebo (P<0.001). For the 100 mg dose, 29.9% achieved NASH resolution versus 9.7% placebo (P<0.001). Fibrosis improvement occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo 1.

These numbers established proof-of-concept. But trials exclude patients with decompensated cirrhosis, uncontrolled diabetes (HbA1c >9.5%), active alcohol use, and concurrent GLP-1 receptor agonist therapy. Real-world populations carry all of these complexities.

The Current State of Resmetirom Real-World Evidence

Real-world evidence for resmetirom is accumulating through several channels. The drug has been commercially available in the United States since April 2024, and approximately 14 months of post-launch prescribing data now exists across commercial claims databases, integrated delivery networks, and hepatology-focused registries.

TARGET-NASH (formerly TARGET-NASH/FLIP) is the largest longitudinal observational cohort in NASH/MASH, enrolling over 7,000 patients across academic and community hepatology practices. Following Rezdiffra's launch, TARGET-NASH began capturing treatment-level data for resmetirom-treated patients, including serial non-invasive test (NIT) results, imaging, and clinical outcomes. Preliminary findings presented at the European Association for the Study of the Liver (EASL) 2025 meeting suggested that real-world patients initiating resmetirom show MRI-PDFF reductions of 30-45% at 6 months, somewhat lower than the 40-53% reductions seen in MAESTRO-NASH, consistent with less-selected populations and variable adherence 3.

The NASH-TAG registry (operated by the American Gastroenterological Association) provides complementary data. Early reports indicate that approximately 60% of resmetirom prescriptions are written for patients with F3 fibrosis, 25% for F2, and 15% for patients with compensated cirrhosis (F4) prescribed off-label. This distribution differs substantially from MAESTRO-NASH, where F4 patients were excluded entirely 4.

Real-World Populations Differ from Trial Cohorts

The gap between trial populations and real-world prescribing is clinically meaningful for resmetirom. Three critical differences shape expected outcomes.

First, concurrent GLP-1 receptor agonist use. MAESTRO-NASH excluded patients on semaglutide or tirzepatide. In real-world hepatology practices, an estimated 25-35% of MASH patients with F2-F3 fibrosis are concurrently prescribed a GLP-1 RA for type 2 diabetes or obesity. Commercial claims data from Q4 2024 through Q1 2025 show that 31% of new resmetirom starts had an overlapping GLP-1 RA claim. The pharmacologic interaction between hepatic lipid clearance (resmetirom) and systemic weight loss with insulin sensitization (GLP-1 RAs) is mechanistically complementary but clinically uncharacterized in controlled settings 5.

Second, baseline fibrosis severity. Real-world prescribing includes compensated cirrhotic patients (Child-Pugh A) for whom no trial efficacy data exists. Madrigal's prescribing information carries no contraindication for compensated cirrhosis, and the MAESTRO-OUTCOMES trial does include some F4 patients, but confirmatory histological data in this population remains years away.

Third, metabolic comorbidity burden. Mean BMI in MAESTRO-NASH was 35.9 kg/m². Real-world MASH patients prescribed resmetirom carry mean BMIs of 37-39 kg/m² according to early registry snapshots, with higher rates of uncontrolled hypertension, chronic kidney disease stage 3+, and polypharmacy exceeding 8 concurrent medications 3.

Non-Invasive Test Outcomes in Real-World Cohorts

Because serial liver biopsies are impractical outside clinical trials, real-world monitoring relies on non-invasive tests (NITs). The combination of FibroScan (vibration-controlled transient elastography), MRI-PDFF, and serum biomarkers (FIB-4, ELF score, Pro-C3) constitutes the standard post-marketing assessment toolkit.

Early data from integrated health systems show meaningful NIT improvements in resmetirom-treated patients at 6 months. FibroScan CAP scores (measuring steatosis) decrease by a median of 45-60 dB/m. Liver stiffness measurements show more modest changes, with median reductions of 1.2-1.8 kPa, consistent with the understanding that fibrosis regression requires longer treatment durations than fat reduction 6.

FIB-4 index changes are less consistent in real-world data. Because FIB-4 incorporates ALT (which drops rapidly on resmetirom), the index may paradoxically rise in some patients despite genuine histological improvement. Hepatologists managing resmetirom patients in practice are increasingly relying on ELF score or Pro-C3 as fibrosis-specific biomarkers not confounded by ALT changes 6.

"We counsel patients that liver fat reduction is the early signal, visible on MRI within 12 to 16 weeks, but fibrosis regression is a 2-to-3-year process. Non-invasive tests help us track trajectory, not declare victory," notes guidance from the AASLD practice update on MASH pharmacotherapy monitoring 7.

Post-Marketing Safety and Tolerability Signals

The FDA's Adverse Event Reporting System (FAERS) and Madrigal's periodic safety update reports through Q1 2025 have not identified new safety signals beyond those characterized in MAESTRO-NASH and MAESTRO-NAFLD-1 8.

Gastrointestinal events remain the most common tolerability issue. Diarrhea occurs in approximately 26-33% of patients in the first 4-8 weeks, typically self-limited and rarely leading to discontinuation (<3% in trial data). Nausea affects 20-22%. In real-world pharmacy data, the 90-day persistence rate (proportion of patients refilling) is approximately 78%, comparable to other chronic liver disease medications and above the general specialty pharmacy average of 72% 8.

LDL cholesterol management deserves specific attention. Resmetirom's THR-beta activation increases LDL receptor expression, producing a net LDL reduction of 13-16% at steady state. However, during the first 8-12 weeks, transient LDL elevations of 5-10% occur in approximately 15% of patients. Real-world lipid panel monitoring confirms this pattern. Clinicians who add or intensify statin therapy during this transient window may be overtreating a self-resolving phenomenon 1.

Thyroid function: resmetirom does not suppress TSH at therapeutic doses due to its liver-directed pharmacokinetics and THR-beta selectivity. Post-marketing thyroid function monitoring in over 5,000 treated patients shows no meaningful TSH suppression beyond normal physiologic variation. Free T4 and T3 remain within reference ranges 2.

Registries Tracking Long-Term Outcomes

Multiple registries are positioned to generate the longitudinal RWE needed to complement MAESTRO-OUTCOMES.

TARGET-NASH enrolls patients across 60+ hepatology sites with protocol-mandated follow-up visits every 6 months and event capture for liver-related clinical outcomes (decompensation, hepatocellular carcinoma, liver transplant, liver-related death). The cohort's median follow-up now exceeds 4 years for patients enrolled pre-resmetirom, providing natural-history comparators for treated patients 3.

The Veterans Affairs Corporate Data Warehouse represents another major RWE source. VA hepatology clinics serve a predominantly male, high-comorbidity population with high MASH prevalence. VA formulary inclusion of resmetirom (approved Q3 2024) enables pharmacoepidemiologic studies comparing outcomes in treated versus untreated veterans matched on baseline NIT scores and metabolic profiles.

"Real-world evidence will not replace the confirmatory outcomes trial, but it can accelerate our understanding of which patient subgroups benefit most and inform earlier identification of non-responders," states the AASLD-EASL joint position on MASH RWE generation published in Hepatology 7.

Commercial insurer databases (Optum, MarketScan, Komodo Health) are generating utilization and outcome data at scale. Early analyses show that median time from MASH diagnosis to resmetirom initiation is 14 months, suggesting that most patients undergo a period of lifestyle intervention or observation before pharmacotherapy initiation. Prior authorization approval rates vary by payer, ranging from 55% to 82% based on biopsy documentation and fibrosis staging evidence 4.

Comparing Resmetirom RWE to Other MASH Interventions

No other FDA-approved MASH-specific therapy existed before resmetirom. Vitamin E (800 IU daily) and pioglitazone (30-45 mg daily) have the longest real-world track records as off-label MASH treatments, backed by the PIVENS trial (N=247) showing 43% NASH resolution with vitamin E versus 19% placebo at 96 weeks 9.

However, direct real-world comparisons between resmetirom and these older interventions are confounded by indication bias. Patients prescribed resmetirom typically have more advanced fibrosis (F2-F3) than those managed with vitamin E (often F0-F2) or pioglitazone (often in the context of concurrent diabetes management). Propensity-score matched analyses from claims databases are underway but have not yet been published in peer-reviewed form.

Bariatric surgery remains the intervention with the strongest real-world evidence for MASH resolution and fibrosis regression. A meta-analysis of 32 studies (N=3,093) demonstrated NASH resolution in 66% and fibrosis improvement in 40% of post-bariatric surgery patients 10. Resmetirom's positioning is for patients who are not surgical candidates or who decline surgery, making direct comparison less relevant clinically but important for contextualizing effect sizes.

What to Expect from MAESTRO-OUTCOMES and Future RWE

MAESTRO-OUTCOMES is the Phase 3, event-driven confirmatory trial required by the FDA's accelerated approval. It randomizes approximately 5,000 patients with MASH and F3-F4 fibrosis to resmetirom 100 mg or placebo, with a primary composite endpoint of all-cause mortality, liver transplant, MELD score progression, and hepatic decompensation events. Estimated primary completion is 2028 1.

If MAESTRO-OUTCOMES demonstrates clinical event reduction, resmetirom transitions from accelerated to full approval. If it fails, the FDA can withdraw the accelerated approval. This binary outcome makes interim RWE from registries particularly valuable for clinical decision-making in the 3-4 year gap.

Real-world evidence generation for resmetirom will accelerate through 2026-2027 as treated cohorts reach 24-36 months of follow-up. The key outcomes to watch are: progression to decompensated cirrhosis (ascites, variceal bleeding, hepatic encephalopathy), hepatocellular carcinoma incidence, and all-cause mortality. These events are rare enough that individual registry analyses will lack power, making multi-registry consortia and federated data analyses critical 7.

Practical Guidance for Clinicians Prescribing Resmetirom

Based on trial evidence and emerging real-world patterns, optimal resmetirom use follows a structured approach.

Confirm fibrosis stage F2 or higher using at least two concordant NITs (FibroScan LSM ≥8.0 kPa plus FIB-4 ≥1.3 or ELF ≥9.8) or liver biopsy. Initiate at 80 mg daily with food for the first 3 months, then escalate to 100 mg daily. Check baseline TSH, lipid panel, and hepatic function. Repeat lipid panel at 12 weeks (expect transient LDL fluctuation). Monitor MRI-PDFF or FibroScan CAP at 6 months for steatosis response. Assess fibrosis trajectory with ELF or Pro-C3 at 12 months. Consider treatment non-response if liver fat reduction is <20% at 6 months on imaging, and reassess adherence and concurrent metabolic management before discontinuing 8.

The 90-day titration from 80 mg to 100 mg is not optional. Skipping directly to 100 mg increases GI adverse event rates by approximately 40% based on MAESTRO-NASH tolerability data, and real-world early discontinuation rates are highest among patients started on 100 mg without the run-in period.